FDA-APPROVED OPTUNE PAX ADDS A NEW WEAPON AGAINST LOCALLY ADVANCED PANCREATIC CANCER A new type of cancer treatment is giving some patients with locally advanced pancreatic cancer another option. In February 2026, the U.S. FDA approved Optune Pax, a wearable device that delivers Tumor Treating Fields (TTFields) to the abdomen. It is approved for adults with locally advanced pancreatic cancer, used together with the chemotherapy drugs gemcitabine and nab-paclitaxel. (U.S. Food and Drug Administration) HOW IT WORKS: WEARABLE DEVICE → adhesive arrays are placed on the skin of the abdomen → the device delivers alternating electrical fields called Tumor Treating Fields → the fields interact with dividing cancer cells → they can disrupt processes involved in cell division → the treatment is given together with gemcitabine + nab-paclitaxel chemotherapy WHY THIS MATTERS: Pancreatic cancer remains one of the most difficult cancers to treat, particularly when a tumor is locally advanced and cannot initially be removed surgically. Optune Pax offers a different approach: instead of relying only on drugs, it adds electrical fields designed to interfere with cancer-cell division. The treatment is also non-invasive and portable. Patients can receive the therapy at home while continuing their other cancer treatment. (U.S. Food and Drug Administration) REFERENCES: • U.S. FDA — “FDA Approves First-of-Its-Kind Device to Treat Pancreatic Cancer,” February 12, 2026. (U.S. Food and Drug Administration) • Babiker HM, et al. — “Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study,” 2025. (PubMed) • ClinicalTrials.gov — PANOVA-3, NCT03377491. (ClinicalTrials.gov) • Optune Pax — FDA-approved indication and safety information. (Optune Pax) DISCLAIMER: This content is for educational and informational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease or medical condition. Optune Pax is an FDA-approved treatment for a specific group of adults